Scienture Holdings, Inc. announced a securities purchase agreement with institutional investors for 3,225,000 shares of common stock at $1.20 per share.
The gross proceeds from the offering are expected to be approximately $3.9 million before expenses.
The offering is expected to close on August 15, 2025, subject to customary closing conditions.
Securities Purchase Agreement
3,225,000 shares of common stock purchased at $1.20 per share.
Gross Proceeds
Approximately $3.9 million expected before deducting fees.
Closing Date
Offering expected to close on August 15, 2025.
- The company aims to raise funds for its pharmaceutical operations through the offering.
- The offering is part of Scienture Holdings' strategy to provide enhanced value to patients, physicians, and caregivers.
- Maxim Group LLC is the sole placement agent for the offering.
Scienture Holdings' entry into the registered direct offering signifies a strategic move to support its pharmaceutical operating companies and enhance its market value.